🇺🇸 FDA
Company

DiaMedica

DiaMedica Therapeutics

DMAC pharma USA

Quick answer

DiaMedica is a pharma company (DMAC) headquartered in MINNEAPOLIS, MN, USA with 7 tracked pipeline programs.

Pipeline (7)

project

Recombinant human tissue kallikrein

Acute Stroke

Phase 3 · small_molecule · active

1 trials project

DM199

Diabetes Type 2

Phase 2 · small_molecule · completed

1 trials project

DM199

Kidney Diseases

Phase 2 · small_molecule · completed

1 trials project

Recombinant human tissue kallikrein

Acute Ischemic Stroke

Phase 2 · small_molecule · completed

1 trials project

DM199

Chronic Kidney Disease

Phase 1 · small_molecule · completed

1 trials project

Recombinant human tissue kallikrein

Stroke

Phase 1 · small_molecule · completed

1 trials project

DM199

Pre-Eclampsia

Unknown · mab · terminated

1 trials

Patents (8)

patent

US 12329805

Dosage forms of tissue kallikrein 1

Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11857608

Dosage forms of tissue kallikrein 1

Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11725043

Ulinastatin polypeptides

Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9839678

Human tissue kallikrein 1 glycosylation isoforms

Expires Mon Dec 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9616015

Formulations of human tissue kallikrein-1 for parenteral delivery and related me

Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9364521

Human tissue kallikrein 1 glycosylation isoforms

Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 8673964

Use of drug combinations for treating insulin resistance

Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 8501695

Tissue kallikrein for the treatment of diseases associated with amyloid protein

Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)